Jeffrey M. Witkin - Publications

Affiliations: 
Eli Lilly, Indianapolis, IN, United States 

150 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Eiler WJA, Gleason SD, Smith JL, Witkin JM. A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity. Pharmacology, Biochemistry, and Behavior. PMID 31202811 DOI: 10.1016/j.pbb.2019.06.005  0.328
2019 Knopp KL, Simmons RMA, Guo W, Adams BL, Gardinier KM, Gernert DL, Ornstein PL, Porter W, Reel J, Ding C, Wang H, Qian Y, Burris KD, Need A, Barth V, ... ... Witkin J, et al. Modulation of TARP γ8-containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain. The Journal of Pharmacology and Experimental Therapeutics. PMID 30910921 DOI: 10.1124/Jpet.118.250126  0.338
2018 Balcer OM, Seager MA, Gleason SD, Li X, Rasmussen K, Maxwell JK, Nomikos G, Degroot A, Witkin JM. Evaluation of 5-HT receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice. Behavioural Brain Research. 360: 270-278. PMID 30543903 DOI: 10.1016/J.Bbr.2018.12.019  0.349
2018 Maxwell J, Gleason SD, Falcone J, Svensson K, Balcer OM, Li X, Witkin JM. Effects of 5-HT Receptor Antagonists on Behaviors of Mice that Detect Drugs Used in the Treatment of Anxiety, Depression, or Schizophrenia. Behavioural Brain Research. PMID 30471311 DOI: 10.1016/J.Bbr.2018.11.019  0.338
2018 Witkin JM, Shenvi RA, Li X, Gleason SD, Weiss J, Morrow D, Catow JT, Wakulchik M, Ohtawa M, Lu HH, Martinez MD, Schkeryantz JM, Carpenter TS, Lightstone FC, Cerne R. Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies. Biochemical Pharmacology. PMID 29940173 DOI: 10.1016/J.Bcp.2018.06.022  0.419
2018 Witkin JM, Smith JL, Ping X, Gleason SD, Poe MM, Li G, Jin X, Hobbs J, Schkeryantz JM, McDermott JS, Alatorre AI, Siemian JN, Cramer JW, Airey DC, Methuku KR, et al. Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABA receptors: Improved bioavailability enhances anticonvulsant efficacy. Neuropharmacology. 137: 332-343. PMID 29778948 DOI: 10.1016/J.Neuropharm.2018.05.006  0.371
2018 Methuku KR, Li X, Cerne R, Gleason SD, Schkeryantz JM, Tiruveedhula VVNPB, Golani LK, Li G, Poe MM, Rahman MT, Cook JM, Fisher JL, Witkin JM. An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABA receptors. Pharmacology, Biochemistry, and Behavior. PMID 29715490 DOI: 10.1016/J.Pbb.2018.04.009  0.316
2018 Xu NZ, Ernst M, Treven M, Cerne R, Wakulchik M, Li X, Jones TM, Gleason SD, Morrow D, Schkeryantz JM, Rahman MT, Li G, Poe MM, Cook JM, Witkin JM. Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice. Psychopharmacology. PMID 29374303 DOI: 10.1007/S00213-018-4832-9  0.327
2018 Kato AS, Witkin JM. Protein complexes as psychiatric and neurological drug targets. Biochemical Pharmacology. PMID 29330067 DOI: 10.1016/J.Bcp.2018.01.018  0.309
2017 Bruns RF, Mitchell SN, Wafford KA, Harper AJ, Shanks EA, Carter G, O'Neill MJ, Murray TK, Eastwood BJ, Schaus JM, Beck JP, Hao J, Witkin JM, Li X, Chernet E, et al. Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders. Neuropharmacology. PMID 29102759 DOI: 10.1016/J.Neuropharm.2017.10.032  0.392
2017 Witkin JM, Schober DA, Gleason SD, Catlow JT, Porter WJ, Reel J, Jin X, Hobbs J, Gehlert D, Gernert DL, Gardinier KM, Kato AS, Ping X, Smith JL. Targeted Blockade of TARP-g8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611). Cns & Neurological Disorders Drug Targets. PMID 29090671 DOI: 10.2174/1871527316666171101132047  0.368
2017 Kato AS, Witkin JM. Auxiliary subunits of AMPA receptors: the discovery of a forebrain-selective antagonist, LY3130481/CERC-611. Biochemical Pharmacology. PMID 28987594 DOI: 10.1016/J.Bcp.2017.09.015  0.348
2017 Yuen E, Swanson S, Witkin JM. Prediction of human efficacious antidepressant doses using the mouse forced swim test. Pharmacology, Biochemistry, and Behavior. PMID 28888484 DOI: 10.1016/J.Pbb.2017.09.002  0.346
2017 Lee MR, Gardinier KM, Gernert DL, Schober DA, Wright RA, Wang H, Qian Y, Witkin JM, Nisenbaum ES, Kato AS. Structural Determinants of the γ-8 TARP Dependent AMPA Receptor Antagonist. Acs Chemical Neuroscience. PMID 28825787 DOI: 10.1021/Acschemneuro.7B00186  0.318
2017 Witkin JM, Li J, Gilmour G, Mitchell SN, Carter G, Gleason SD, Seidel WF, Eastwood BJ, McCarthy A, Porter WJ, Reel J, Gardinier KM, Kato AS, Wafford KA. Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-γ8-associated AMPA receptors. Neuropharmacology. PMID 28757050 DOI: 10.1016/J.Neuropharm.2017.07.028  0.374
2017 Rodriguez MM, Overshiner C, Leander JD, Li X, Morrow D, Conway RG, Nelson DL, Briner K, Witkin JM. Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive-Compulsive Disorder. Frontiers in Psychiatry. 8: 89. PMID 28588509 DOI: 10.3389/Fpsyt.2017.00089  0.651
2017 Witkin JM, Cerne R, Wakulchik M, S J, Gleason SD, Jones TM, Li G, Arnold LA, Li JX, Schkeryantz JM, Methuku KR, Cook JM, Poe MM. Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors. Pharmacology, Biochemistry, and Behavior. PMID 28442369 DOI: 10.1016/J.Pbb.2017.04.009  0.38
2016 Witkin JM, Rorick-Kehn LM, Benvenga MJ, Adams BL, Gleason SD, Knitowski KM, Li X, Chaney S, Falcone JF, Smith JW, Foss J, Lloyd K, Catlow JT, McKinzie DL, Svensson KA, et al. Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. Pharmacology Research & Perspectives. 4: e00275. PMID 28097008 DOI: 10.1002/Prp2.275  0.437
2016 Poe MM, Methuku KR, Li G, Verma AR, Teske KA, Stafford DC, Arnold LA, Cramer JW, Jones TM, Cerne R, Krambis MJ, Witkin JM, Jambrina E, Rehman S, Ernst M, et al. Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy. Journal of Medicinal Chemistry. 59: 10800-10806. PMID 27933953 DOI: 10.1021/Acs.Jmedchem.6B01332  0.34
2016 Dressman BA, Tromiczak EG, Chappell MD, Tripp AE, Quimby SJ, Vetman T, Fivush AM, Matt J, Jaramillo C, Li R, Khilevich A, Blanco MJ, Smith SC, Carpintero M, de Diego JE, ... ... Witkin JM, et al. Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depression. Bioorganic & Medicinal Chemistry Letters. PMID 27836401 DOI: 10.1016/J.Bmcl.2016.10.067  0.389
2016 Kato AS, Burris KD, Gardinier KM, Gernert DL, Porter WJ, Reel J, Ding C, Tu Y, Schober DA, Lee MR, Heinz BA, Fitch TE, Gleason SD, Catlow JT, Yu H, ... ... Witkin JM, et al. Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism. Nature Medicine. PMID 27820603 DOI: 10.1038/Nm.4221  0.366
2016 Eiler WJ, Chen Y, Slieker LJ, Ardayfio PA, Statnick MA, Witkin JM. Consequences of constitutive deletion of melanin-concentrating hormone-1 receptors for feeding and foraging behaviors of mice. Behavioural Brain Research. 316: 271-278. PMID 27633558 DOI: 10.1016/J.Bbr.2016.09.028  0.341
2016 Witkin JM, Monn JA, Schoepp DD, Li X, Overshiner CD, Mitchell SN, Carter G, Johnson B, Rasmussen K, Rorick-Kehn LM. The Rapidly-Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. The Journal of Pharmacology and Experimental Therapeutics. PMID 27189960 DOI: 10.1124/Jpet.116.233627  0.407
2016 Rorick-Kehn LM, Ciccocioppo R, Wong CJ, Witkin JM, Martinez-Grau MA, Stopponi S, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, et al. A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models. Alcoholism, Clinical and Experimental Research. PMID 27084498 DOI: 10.1111/Acer.13052  0.391
2016 Gardinier KM, Gernert DL, Porter WJ, Reel JK, Ornstein PL, Spinazze P, Stevens FC, Hahn P, Hollinshead SP, Mayhugh D, Schkeryantz J, Khilevich A, De Frutos O, Gleason SD, Kato AS, ... ... Witkin JM, et al. The Discovery of The First α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent Upon Transmembrane AMPA Receptor Regulatory Protein (TARP) Gamma-8. Journal of Medicinal Chemistry. PMID 27067148 DOI: 10.1021/Acs.Jmedchem.6B00125  0.364
2015 Witkin JM, Ornstein PL, Mitch CH, Li R, Smith SC, Heinz BA, Wang XS, Xiang C, Carter JH, Anderson WH, Li X, Broad LM, Pasqui F, Fitzjohn SM, Sanger HE, et al. In Vitro Pharmacological and Rat Pharmacokinetic Characterization of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist. Neuropharmacology. PMID 26748052 DOI: 10.1016/J.Neuropharm.2015.12.021  0.354
2015 Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM. A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26585287 DOI: 10.1038/Npp.2015.348  0.381
2015 Witkin JM, Gleason SD, Carter RB, Dykstra LA. Obituary: J. David LEander, Ph.D. : (April 8, 1944-November 14, 2014). Psychopharmacology. 232: 1175-6. PMID 25697862 DOI: 10.1007/S00213-015-3885-2  0.684
2014 Witkin JM, Overshiner C, Li X, Catlow JT, Wishart GN, Schober DA, Heinz BA, Nikolayev A, Tolstikov VV, Anderson WH, Higgs RE, Kuo MS, Felder CC. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. The Journal of Pharmacology and Experimental Therapeutics. 351: 448-56. PMID 25187432 DOI: 10.1124/Jpet.114.216804  0.344
2014 Toledo MA, Pedregal C, Lafuente C, Diaz N, Martinez-Grau MA, Jiménez A, Benito A, Torrado A, Mateos C, Joshi EM, Kahl SD, Rash KS, Mudra DR, Barth VN, Shaw DB, ... ... Witkin JM, et al. Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold. Journal of Medicinal Chemistry. 57: 3418-29. PMID 24678969 DOI: 10.1021/Jm500117R  0.378
2014 Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC, Ciccocioppo R. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacology & Therapeutics. 141: 283-99. PMID 24189487 DOI: 10.1016/J.Pharmthera.2013.10.011  0.355
2014 Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 77: 131-44. PMID 24071566 DOI: 10.1016/J.Neuropharm.2013.09.021  0.442
2013 Gleason SD, Li X, Smith IA, Ephlin JD, Wang XS, Heinz BA, Carter JH, Baez M, Yu J, Bender DM, Witkin JM. mGlu2/3 agonist-induced hyperthermia: an in vivo assay for detection of mGlu2/3 receptor antagonism and its relation to antidepressant-like efficacy in mice. Cns & Neurological Disorders Drug Targets. 12: 554-66. PMID 23574174 DOI: 10.2174/18715273113129990079  0.316
2013 Witkin JM, Leucke S, Thompson LK, Lynch RA, Ding C, Heinz B, Catlow JT, Gleason SD, Li X. Further evaluation of the neuropharmacological determinants of the antidepressant-like effects of curcumin. Cns & Neurological Disorders Drug Targets. 12: 498-505. PMID 23574162  0.309
2013 Barth V, Need AB, Tzavara ET, Giros B, Overshiner C, Gleason SD, Wade M, Johansson AM, Perry K, Nomikos GG, Witkin JM. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder. The Journal of Pharmacology and Experimental Therapeutics. 344: 501-10. PMID 23197772 DOI: 10.1124/Jpet.112.198895  0.386
2011 Eiler WJ, Baez M, Yu J, Witkin JM. mGlu5 receptor deletion reduces relapse to food-seeking and prevents the anti-relapse effects of mGlu5 receptor blockade in mice. Life Sciences. 89: 862-7. PMID 21983299 DOI: 10.1016/J.Lfs.2011.09.014  0.389
2011 Gleason SD, Yin T, Little SP, Delapp N, Witkin JM. Multiple dopamine receptors mediate the discriminative stimulus effects of dihydrexidine in rats. Behavioural Pharmacology. 22: 531-9. PMID 21836463 DOI: 10.1097/Fbp.0B013E328349Aace  0.385
2011 Kaminski RM, Núñez-Taltavull JF, Budziszewska B, LasoÅ„ W, Gasior M, Zapata A, Shippenberg TS, Witkin JM. Effects of cocaine-kindling on the expression of NMDA receptors and glutamate levels in mouse brain. Neurochemical Research. 36: 146-52. PMID 20927585 DOI: 10.1007/S11064-010-0284-2  0.352
2010 Farley S, Apazoglou K, Witkin JM, Giros B, Tzavara ET. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 13: 1207-18. PMID 20059803 DOI: 10.1017/S1461145709991076  0.378
2009 Witkin JM, Li X. New approaches to the pharmacological management of major depressive disorder. Advances in Pharmacology (San Diego, Calif.). 57: 347-79. PMID 20230766 DOI: 10.1016/S1054-3589(08)57009-8  0.329
2009 Gehlert DR, Rasmussen K, Shaw J, Li X, Ardayfio P, Craft L, Coskun T, Zhang HY, Chen Y, Witkin JM. Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. The Journal of Pharmacology and Experimental Therapeutics. 329: 429-38. PMID 19182070 DOI: 10.1124/Jpet.108.143362  0.304
2008 Witkin JM. Animal models of obsessive-compulsive disorder. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 9.30. PMID 18972380 DOI: 10.1002/0471142301.Ns0930S45  0.349
2008 Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 105: 10978-83. PMID 18678919 DOI: 10.1073/Pnas.0800567105  0.35
2008 Witkin JM, Baez M, Yu J, Eiler WJ. mGlu5 receptor deletion does not confer seizure protection to mice. Life Sciences. 83: 377-80. PMID 18675825 DOI: 10.1016/J.Lfs.2008.07.001  0.385
2008 Pilc A, Chaki S, Nowak G, Witkin JM. Mood disorders: regulation by metabotropic glutamate receptors. Biochemical Pharmacology. 75: 997-1006. PMID 18164691 DOI: 10.1016/J.Bcp.2007.09.021  0.358
2007 Gleason SD, Witkin JM. A parametric analysis of punishment frequency as a determinant of the response to chlordiazepoxide in the Vogel conflict test in rats. Pharmacology, Biochemistry, and Behavior. 87: 380-5. PMID 17583779 DOI: 10.1016/J.Pbb.2007.05.011  0.397
2007 O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Current Drug Targets. 8: 603-20. PMID 17504104 DOI: 10.2174/138945007780618517  0.336
2007 Witkin JM, Baez M, Yu J, Barton ME, Shannon HE. Constitutive deletion of the serotonin-7 (5-HT(7)) receptor decreases electrical and chemical seizure thresholds. Epilepsy Research. 75: 39-45. PMID 17485199 DOI: 10.1016/J.Eplepsyres.2007.03.017  0.372
2007 Bleakman D, Alt A, Witkin JM. AMPA receptors in the therapeutic management of depression. Cns & Neurological Disorders Drug Targets. 6: 117-26. PMID 17430149 DOI: 10.2174/187152707780363258  0.371
2007 Witkin JM, Marek GJ, Johnson BG, Schoepp DD. Metabotropic glutamate receptors in the control of mood disorders. Cns & Neurological Disorders Drug Targets. 6: 87-100. PMID 17430147 DOI: 10.2174/187152707780363302  0.358
2007 Svenningsson P, Tzavara ET, Qi H, Carruthers R, Witkin JM, Nomikos GG, Greengard P. Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 4201-9. PMID 17428998 DOI: 10.1523/Jneurosci.3110-06.2007  0.348
2007 Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE, Witkin JM. Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. Neuropharmacology. 52: 1482-7. PMID 17418283 DOI: 10.1016/J.Neuropharm.2007.02.005  0.372
2007 Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology. 193: 121-36. PMID 17384937 DOI: 10.1007/S00213-007-0758-3  0.438
2007 Kaminski RM, Witkin JM, Shippenberg TS. Pharmacological and genetic manipulation of kappa opioid receptors: effects on cocaine- and pentylenetetrazol-induced convulsions and seizure kindling. Neuropharmacology. 52: 895-903. PMID 17126860 DOI: 10.1016/J.Neuropharm.2006.10.007  0.408
2006 Gleason SD, Witkin JM. Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine. Psychopharmacology. 186: 25-31. PMID 16575553 DOI: 10.1007/S00213-006-0342-2  0.41
2006 Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, Bleakman D, Witkin JM. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology. 185: 240-7. PMID 16470401 DOI: 10.1007/S00213-005-0292-0  0.398
2006 Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochemical Pharmacology. 71: 1273-88. PMID 16442080 DOI: 10.1016/J.Bcp.2005.12.022  0.366
2006 Tzavara ET, Bymaster FP, Overshiner CD, Davis RJ, Perry KW, Wolff M, McKinzie DL, Witkin JM, Nomikos GG. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Molecular Psychiatry. 11: 187-95. PMID 16231039 DOI: 10.1038/Sj.Mp.4001763  0.33
2006 Smith DG, Davis RJ, Rorick-Kehn L, Morin M, Witkin JM, McKinzie DL, Nomikos GG, Gehlert DR. Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 1135-45. PMID 16205780 DOI: 10.1038/Sj.Npp.1300913  0.351
2006 Li X, Morrow D, Witkin JM. Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sciences. 78: 1933-9. PMID 16182315 DOI: 10.1016/J.Lfs.2005.08.002  0.425
2006 Witkin JM, Eiler WJA. Antagonism of metabotropic glutamate group II receptors in the potential treatment of neurological and neuropsychiatric disorders Drug Development Research. 67: 757-769. DOI: 10.1002/Ddr.20144  0.363
2005 Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends in Pharmacological Sciences. 26: 609-17. PMID 16260047 DOI: 10.1016/J.Tips.2005.10.006  0.377
2005 Witkin JM, Tzavara ET, Nomikos GG. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behavioural Pharmacology. 16: 315-31. PMID 16148437 DOI: 10.1097/00008877-200509000-00005  0.352
2005 Kaminski RM, Shippenberg TS, Witkin JM, Rocha BA. Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures. Neuroscience Letters. 382: 51-5. PMID 15911120 DOI: 10.1016/J.Neulet.2005.02.056  0.358
2004 Witkin JM, Nelson DL. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacology & Therapeutics. 103: 1-20. PMID 15251226 DOI: 10.1016/J.Pharmthera.2004.05.001  0.333
2004 Gasior M, Witkin JM, Goldberg SR, Munzar P. Chlormethiazole potentiates the discriminative stimulus effects of methamphetamine in rats. European Journal of Pharmacology. 494: 183-9. PMID 15212973 DOI: 10.1016/J.Ejphar.2004.05.011  0.481
2004 Gasior M, Kaminski R, Witkin JM. Pharmacological modulation of GABA(B) receptors affects cocaine-induced seizures in mice. Psychopharmacology. 174: 211-9. PMID 14985936 DOI: 10.1007/s00213-003-1743-0  0.336
2004 Witkin JM, Morrow D, Li X. A rapid punishment procedure for detection of anxiolytic compounds in mice. Psychopharmacology. 172: 52-7. PMID 14504684 DOI: 10.1007/S00213-003-1618-4  0.368
2003 Kaminski RM, Gasior M, Carter RB, Witkin JM. Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. European Journal of Pharmacology. 474: 217-22. PMID 12921865 DOI: 10.1016/S0014-2999(03)02086-7  0.676
2003 Li X, Witkin JM, Need AB, Skolnick P. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cellular and Molecular Neurobiology. 23: 419-30. PMID 12825836 DOI: 10.1023/A:1023648923447  0.408
2003 Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. British Journal of Pharmacology. 138: 544-53. PMID 12598408 DOI: 10.1038/Sj.Bjp.0705100  0.34
2003 Zapata A, Gasior M, Geter-Douglass B, Tortella FC, Newman AH, Witkin JM. Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan. Pharmacology, Biochemistry, and Behavior. 74: 313-23. PMID 12479950 DOI: 10.1016/S0091-3057(02)01000-6  0.411
2002 Witkin JM. Some contextual and historical determinants of the effects of chlordiazepoxide on punished responding of rats. Psychopharmacology. 163: 488-94. PMID 12373449 DOI: 10.1007/S00213-002-1135-X  0.365
2002 Witkin JM, Gasior M, Schad C, Zapata A, Shippenberg T, Hartman T, Slusher BS. NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology. 43: 348-56. PMID 12243764 DOI: 10.1016/S0028-3908(02)00124-7  0.379
2002 Gasior M, Jaszyna M, Munzar P, Witkin JM, Goldberg SR. Caffeine potentiates the discriminative-stimulus effects of nicotine in rats. Psychopharmacology. 162: 385-95. PMID 12172692 DOI: 10.1007/S00213-002-1113-3  0.323
2002 Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proceedings of the National Academy of Sciences of the United States of America. 99: 3182-7. PMID 11880651 DOI: 10.1073/Pnas.052712799  0.321
2001 Zapata A, Witkin JM, Shippenberg TS. Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses. Neuropharmacology. 41: 351-9. PMID 11522326 DOI: 10.1016/S0028-3908(01)00069-7  0.362
2001 Lindén A, Storvik M, Lakso M, Haapasalo A, Lee D, Witkin JM, Sei Y, Castrén E, Wong G. Increased expression of neuronal Src and tyrosine phosphorylation of NMDA receptors in rat brain after systemic treatment with MK-801. Neuropharmacology. 40: 469-81. PMID 11249956 DOI: 10.1016/S0028-3908(00)00185-4  0.368
2000 Ungard JT, Beekman M, Gasior M, Carter RB, Dijkstra D, Witkin JM. Modification of behavioral effects of drugs in mice by neuroactive steroids. Psychopharmacology. 148: 336-43. PMID 10928304 DOI: 10.1007/S002130050060  0.72
2000 Gasior M, Ungard JT, Beekman M, Carter RB, Witkin JM. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology. 39: 1184-96. PMID 10760361 DOI: 10.1016/S0028-3908(99)00190-2  0.691
2000 Gasior M, Ungard JT, Witkin JM. Lethal seizures predicted after aminophylline therapy in cocaine abusers. European Journal of Pharmacology. 387: R15-6. PMID 10650168 DOI: 10.1016/S0014-2999(99)00801-8  0.341
1999 Geter-Douglass B, Witkin JM. Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology. 146: 280-9. PMID 10541728 DOI: 10.1007/s002130051118  0.316
1999 Gasior M, Ungard JT, Witkin JM. Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. The Journal of Pharmacology and Experimental Therapeutics. 290: 1148-56. PMID 10454489  0.305
1999 Witkin JM, Gasior M, Heifets B, Tortella FC. Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine. The Journal of Pharmacology and Experimental Therapeutics. 289: 703-11. PMID 10215643  0.313
1999 Gasior M, Carter RB, Witkin JM. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends in Pharmacological Sciences. 20: 107-12. PMID 10203866 DOI: 10.1016/S0165-6147(99)01318-8  0.675
1999 Witkin JM, Savtchenko N, Mashkovsky M, Beekman M, Munzar P, Gasior M, Goldberg SR, Ungard JT, Kim J, Shippenberg T, Chefer V. Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine. The Journal of Pharmacology and Experimental Therapeutics. 288: 1298-310. PMID 10027871  0.355
1998 Beekman M, Ungard JT, Gasior M, Carter RB, Dijkstra D, Goldberg SR, Witkin JM. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. The Journal of Pharmacology and Experimental Therapeutics. 284: 868-77. PMID 9495844  0.706
1998 Tirelli E, Geter-Douglass B, Witkin JM. gamma-Aminobutyric acidA agonists differentially augment gnawing induced by indirect-acting dopamine agonists in C57BL/6J mice. The Journal of Pharmacology and Experimental Therapeutics. 284: 116-24. PMID 9435169  0.318
1998 Gasior M, Beekman M, Carter RB, Goldberg SR, Witkin JM. Antiepileptogenic effects of the novel synthetic neuroactive steroid, ganaxolone, against pentylenetetrazol-induced kindled seizures: Comparison with diazepam and valproate Drug Development Research. 44: 21-33. DOI: 10.1002/(Sici)1098-2299(199805)44:1<21::Aid-Ddr4>3.0.Co;2-R  0.692
1997 Gasior M, Carter RB, Goldberg SR, Witkin JM. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. The Journal of Pharmacology and Experimental Therapeutics. 282: 543-53. PMID 9262314  0.679
1997 Witkin JM, Acri JB, Gleeson S, Barrett JE. Blockade of behavioral effects of bretazenil by flumazenil and ZK 93,426 in pigeons. Pharmacology, Biochemistry, and Behavior. 56: 1-7. PMID 8981602 DOI: 10.1016/S0091-3057(96)00120-7  0.6
1996 Tirelli E, Witkin JM. Pharmacological characterization of the enhancement of apomorphine-induced gnawing in mice by cocaine. Pharmacology, Biochemistry, and Behavior. 55: 135-40. PMID 8870049 DOI: 10.1016/0091-3057(96)00067-6  0.357
1996 Witkin JM, Acri JB, Wong G, Gleeson S, Barrett JE. Behavioral and biochemical characterization of benzodiazepine receptor partial agonists in pigeons. The Journal of Pharmacology and Experimental Therapeutics. 277: 87-96. PMID 8613971  0.54
1996 Acri JB, Newman AH, Witkin JM. Benztropine, A Potential Treatment For Cocaine Dependence: Discriminative Stimulus Effects Behavioural Pharmacology. 7: 2. DOI: 10.1097/00008877-199605001-00003  0.318
1996 Acri JB, Shah JH, Newman AH, Belov YP, Basile AS, Sharpe LG, Witkin JM. Behavioral effects and dopamine antagonist properties of N-alkylaminobenzazepines Drug Development Research. 37: 39-47. DOI: 10.1002/(Sici)1098-2299(199601)37:1<39::Aid-Ddr2>3.0.Co;2-N  0.307
1995 Katz JL, Alling K, Shores E, Witkin JM. Effects of D1 dopamine agonists on schedule-controlled behavior in the squirrel monkey. Behavioural Pharmacology. 6: 143-148. PMID 11224321  0.379
1995 Pellón R, Flores P, Alling K, Witkin JM, Katz JL. Pharmacological analysis of the scratching produced by dopamine D2 agonists in squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics. 273: 138-45. PMID 7714759  0.303
1995 Acri JB, Carter SR, Alling K, Geter-Douglass B, Dijkstra D, Wikström H, Katz JL, Witkin JM. Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands. European Journal of Pharmacology. 281: R7-9. PMID 7589197 DOI: 10.1016/0014-2999(95)00411-D  0.362
1995 Acri JB, Wong G, Witkin JM. Stereospecific transduction of behavioral effects via diazepam-insensitive GABAA receptors. European Journal of Pharmacology. 278: 213-23. PMID 7589157 DOI: 10.1016/0014-2999(95)00128-8  0.386
1995 WITKIN JM, STEELE TD, GETER-DOUGLASS B, TORTELLA FC. PRECLINICAL PHARMACOLOGY OF LIGANDS ACTING AT THE STRYCHNINE-INSENSITIVE GLYCINE RECEPTOR OF THE NMDA RECEPTOR Behavioural Pharmacology. 6: 636. DOI: 10.1097/00008877-199508000-00088  0.314
1994 Tirelli E, Witkin JM. Transient hypersensitivity to apomorphine-induced gnawing after termination of acute effects of a single high dose of cocaine. Behavioural Pharmacology. 5: 289-298. PMID 11224278 DOI: 10.1097/00008877-199406000-00006  0.359
1994 Seidleck BK, Thurkauf A, Witkin JM. Evaluation of ADCI against convulsant and locomotor stimulant effects of cocaine: comparison with the structural analogs dizocilpine and carbamazepine. Pharmacology, Biochemistry, and Behavior. 47: 839-44. PMID 8029253 DOI: 10.1016/0091-3057(94)90285-2  0.4
1994 Tirelli E, Witkin JM. Verticalization of behavior elicited by dopaminergic mobilization is qualitatively different between C57BL/6J and DBA/2J mice. Psychopharmacology. 116: 191-200. PMID 7862948 DOI: 10.1007/Bf02245062  0.393
1994 Ginski MJ, Witkin JM. Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists. Psychopharmacology. 114: 573-82. PMID 7855218 DOI: 10.1007/Bf02244987  0.441
1994 Izenwasser S, Terry P, Heller B, Witkin JM, Katz JL. Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors. European Journal of Pharmacology. 263: 277-83. PMID 7843265 DOI: 10.1016/0014-2999(94)90723-4  0.319
1993 French D, Witkin JM. Effects of the dopamine release inhibitor, CGS 10746B, on the locomotor stimulant and discriminative stimulus effects of cocaine and methamphetamine. Pharmacology, Biochemistry, and Behavior. 46: 989-93. PMID 8309980 DOI: 10.1016/0091-3057(93)90233-J  0.411
1993 Witkin JM. Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists. Life Sciences. 53: PL405-10. PMID 7902523 DOI: 10.1016/0024-3205(93)90496-P  0.323
1993 Katz JL, Witkin JM. Behavioral effects of dopaminergic agonists and antagonists alone and in combination in the squirrel monkey. Psychopharmacology. 113: 19-25. PMID 7862823 DOI: 10.1007/Bf02244328  0.371
1992 Witkin JM, Goldberg SR. Effects of d-amphetamine, WIN 35,428, pentobarbital and morphine on schedule-controlled responding in two inbred rat strains that differ in locomotor stimulatory effects of cocaine. Behavioural Pharmacology. 3: 455-463. PMID 11224148 DOI: 10.1097/00008877-199210000-00004  0.396
1992 Witkin JM, Genovese RF, Witkin KM, Chiang PK. Behavioral effects of some diphenyl-substituted antimuscarinics: comparison with cocaine and atropine. Pharmacology, Biochemistry, and Behavior. 41: 377-84. PMID 1574528 DOI: 10.1016/0091-3057(92)90114-U  0.691
1992 Katz JL, Witkin JM. Selective effects of the D1 dopamine receptor agonist, SKF 38393, on behavior maintained by cocaine injection in squirrel monkeys. Psychopharmacology. 109: 241-4. PMID 1365665 DOI: 10.1007/Bf02245508  0.31
1992 Katz JL, Witkin JM. Effects of quinpirole and SKF 38393 alone and in combination in squirrel monkeys trained to discriminate cocaine. Psychopharmacology. 107: 217-20. PMID 1352052 DOI: 10.1007/Bf02245140  0.306
1991 Katz JL, Witkin JM. Behavioral effects of cocaine alone and in combination with selective dopamine antagonists in the squirrel monkey. Psychopharmacology. 103: 33-40. PMID 2006242 DOI: 10.1007/Bf02244070  0.313
1991 Witkin JM, Witkin KM. Effects of some antimuscarinics alone and in combination with chlordiazepoxide on punished and nonpunished behavior of rats. Pharmacology, Biochemistry, and Behavior. 39: 453-6. PMID 1946585 DOI: 10.1016/0091-3057(91)90207-I  0.331
1991 Witkin JM, Schindler CW, Tella SR, Goldberg SR. Interaction of haloperidol and SCH 23390 with cocaine and dopamine receptor subtype-selective agonists on schedule-controlled behavior of squirrel monkeys. Psychopharmacology. 104: 425-31. PMID 1838199 DOI: 10.1007/BF02245644  0.349
1991 Witkin JM, Johnson RE, Jaffe JH, Goldberg SR, Grayson NA, Rice KC, Katz JL. The partial opioid agonist, buprenorphine, protects against lethal effects of cocaine. Drug and Alcohol Dependence. 27: 177-84. PMID 1647294 DOI: 10.1016/0376-8716(91)90037-Y  0.402
1991 Terry P, Witkin J, Katz J. Changes in the stimulus effects of cocaine with training dose Pharmacology Biochemistry and Behavior. 39: 246. DOI: 10.1016/0091-3057(91)90534-9  0.339
1990 Katz JL, Tirelli E, Witkin JM. Stereoselective effects of cocaine. Behavioural Pharmacology. 1: 347-353. PMID 11175419 DOI: 10.1097/00008877-199000140-00008  0.392
1990 Witkin JM, Ricaurte GA, Katz JL. Behavioral effects of N-methylamphetamine and N,N-dimethylamphetamine in rats and squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics. 253: 466-74. PMID 2338643  0.307
1990 Genovese RF, Elsmore TF, Witkin JM. Relationship of the behavioral effects of aprophen, atropine and scopolamine to antagonism of the behavioral effects of physostigmine. Pharmacology, Biochemistry, and Behavior. 37: 117-22. PMID 2263653 DOI: 10.1016/0091-3057(90)90051-I  0.708
1990 Katz JL, Dworkin SI, Dykstra LA, Carter RB, Witkin JM. Some behavioral effects of repeated d-amphetamine administrations Drug Development Research. 20: 31-41. DOI: 10.1002/Ddr.430200105  0.748
1989 Witkin JM, Markowitz RA, Barrett JE. Physostigmine-insensitive behavioral excitatory effects of atropine in squirrel monkeys. Pharmacology, Biochemistry, and Behavior. 32: 309-15. PMID 2734342 DOI: 10.1016/0091-3057(89)90248-7  0.535
1989 Witkin JM, Goldberg SR, Katz JL, Kuhar MJ. Modulation of the lethal effects of cocaine by cholinomimetics. Life Sciences. 45: 2295-301. PMID 2601580 DOI: 10.1016/0024-3205(89)90111-2  0.369
1989 Witkin JM, Goldberg SR, Katz JL. Lethal effects of cocaine are reduced by the dopamine-1 receptor antagonist SCH 23390 but not by haloperidol. Life Sciences. 44: 1285-91. PMID 2523996 DOI: 10.1016/0024-3205(89)90366-4  0.396
1989 Witkin JM. Central and peripheral muscarinic actions of physostigmine and oxotremorine on avoidance responding of squirrel monkeys. Psychopharmacology. 97: 376-82. PMID 2497488 DOI: 10.1007/BF00439454  0.336
1989 Witkin JM, Tortella FC. Behavioral effects of non-opioid antitussive anticonvulsants Drug Development Research. 18: 57-65. DOI: 10.1002/Ddr.430180107  0.451
1988 Tortella FC, Witkin JM, Musacchio JM. Caramiphen: a non-opioid antitussive with potent anticonvulsant properties in rats. European Journal of Pharmacology. 155: 69-75. PMID 3243332 DOI: 10.1016/0014-2999(88)90403-7  0.326
1988 Genovese RF, Elsmore TF, Witkin JM. Environmental influences on the development of tolerance to the effects of physostigmine on schedule-controlled behavior. Psychopharmacology. 96: 462-7. PMID 3149767 DOI: 10.1007/Bf02180025  0.694
1988 Witkin JM, Brady LS, Barrett JE. Antagonism by ketanserin of the behavioral effects of quipazine but not l-5-hydroxytryptophan in squirrel monkeys. Psychopharmacology. 94: 302-5. PMID 3128804 DOI: 10.1007/Bf00174679  0.546
1988 Mansbach RS, Harrod C, Hoffmann SM, Nader MA, Lei Z, Witkin JM, Barrett JE. Behavioral studies with anxiolytic drugs. V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished responding. The Journal of Pharmacology and Experimental Therapeutics. 246: 114-20. PMID 2455786  0.552
1987 Witkin JM, Mansbach RS, Barrett JE, Bolger GT, Skolnick P, Weissman B. Behavioral studies with anxiolytic drugs. IV. Serotonergic involvement in the effects of buspirone on punished behavior of pigeons. The Journal of Pharmacology and Experimental Therapeutics. 243: 970-7. PMID 2891840  0.481
1986 Witkin JM, Barrett JE, Cook JM, Larscheid P. Differential antagonism of diazepam-induced loss of the righting response. Pharmacology, Biochemistry, and Behavior. 24: 963-5. PMID 3012601 DOI: 10.1016/0091-3057(86)90443-0  0.45
1986 Witkin JM, Barrett JE. Benzodiazepine-like effects of inosine on punished behavior of pigeons. Pharmacology, Biochemistry, and Behavior. 24: 121-5. PMID 3003762 DOI: 10.1016/0091-3057(86)90054-7  0.563
1986 Barrett JE, Witkin JM, Mansbach RS, Skolnick P, Weissman BA. Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms. The Journal of Pharmacology and Experimental Therapeutics. 238: 1009-13. PMID 2875168  0.57
1986 Witkin JM, Barrett JE. Interaction of buspirone and dopaminergic agents on punished behavior of pigeons. Pharmacology, Biochemistry, and Behavior. 24: 751-6. PMID 2871566 DOI: 10.1016/0091-3057(86)90585-X  0.548
1986 Barrett JE, Brady LS, Stanley JA, Mansbach RS, Witkin JM. Behavioral studies with anxiolytic drugs. II. Interactions of zopiclone with ethyl-beta-carboline-3-carboxylate and Ro 15-1788 in squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics. 236: 313-9. PMID 2868115  0.523
1985 Barrett JE, Brady LS, Witkin JM, Cook JM, Larscheid P. Interactions between the benzodiazepine receptor antagonist Ro 15-1788 (flumazepil) and the inverse agonist beta-CCE: behavioral studies with squirrel monkeys. Life Sciences. 36: 1407-14. PMID 3920465 DOI: 10.1016/0024-3205(85)90047-5  0.484
1985 Bolger GT, Weissman BA, Lueddens H, Basile AS, Mantione CR, Barrett JE, Witkin JM, Paul SM, Skolnick P. Late evolutionary appearance of 'peripheral-type' binding sites for benzodiazepines. Brain Research. 338: 366-70. PMID 2992689 DOI: 10.1016/0006-8993(85)90170-2  0.359
1985 Barrett JE, Brady LS, Witkin JM. Behavioral studies with anxiolytic drugs. I. Interactions of the benzodiazepine antagonist Ro 15-1788 with chlordiazepoxide, pentobarbital and ethanol. The Journal of Pharmacology and Experimental Therapeutics. 233: 554-9. PMID 2989486  0.545
1985 Witkin JM, Barrett JE. Behavioral effects and benzodiazepine antagonist activity of Ro 15-1788 (flumazepil) in pigeons. Life Sciences. 37: 1587-95. PMID 2932617 DOI: 10.1016/0024-3205(85)90477-1  0.561
1984 Witkin JM, Sickle J, Barrett JE. Potentiation of the behavioral effects of pentobarbital, chlordiazepoxide and ethanol by thyrotropin-releasing hormone. Peptides. 5: 809-13. PMID 6436800 DOI: 10.1016/0196-9781(84)90026-3  0.534
1983 Witkin JM, Leander JD, Dykstra LA. Modification of behavioral effects of morphine, meperidine and normeperidine by naloxone and by morphine tolerance. The Journal of Pharmacology and Experimental Therapeutics. 225: 275-83. PMID 6842391  0.68
1982 Witkin JM, Leander JD. Effects of orally-administered ethanol and tertiary-butanol on fixed-ratio responding of rats. Substance and Alcohol Actions/Misuse. 3: 275-9. PMID 7167864  0.518
1982 Witkin JM, Dykstra LA, Carter RB. Acute tolerance to the discriminative stimulus properties of morphine. Pharmacology, Biochemistry, and Behavior. 17: 223-8. PMID 7134234 DOI: 10.1016/0091-3057(82)90073-9  0.73
1982 Witkin JM, Leander JD. Effects of the appetite stimulant chlordimeform on food and water consumption of rats: comparison with chlordiazepoxide. The Journal of Pharmacology and Experimental Therapeutics. 223: 130-4. PMID 7120114  0.459
1981 Witkin JM, Katz JL, Barrett JE. Effects of methaqualone on punished and nonpunished behavior. The Journal of Pharmacology and Experimental Therapeutics. 218: 1-6. PMID 7241372  0.507
1981 Witkin JM, Barrett JE. Effects of pentobarbital on punished behavior: persistent increases with chronic administration. Psychopharmacology. 75: 324-5. PMID 6798626 DOI: 10.1007/BF00432448  0.458
1980 Witkin JM, Carter RB, Dykstra LA. Discriminative stimulus properties of d-amphetamine-pentobarbital combinations. Psychopharmacology. 68: 269-76. PMID 6771810 DOI: 10.1007/BF00428114  0.735
1976 Witkin JM, Barrett JE. Effects of pentobarbital on punished behavior at different shock intensities. Pharmacology, Biochemistry, and Behavior. 5: 535-8. PMID 1019183 DOI: 10.1016/0091-3057(76)90265-3  0.465
1976 Barrett JE, Witkin JM. Interaction of d-amphetamine with pentobarbital and chlordiazepoxide: effects on punished and unpunished behavior of pigeons. Pharmacology, Biochemistry, and Behavior. 5: 285-92. PMID 996061 DOI: 10.1016/0091-3057(76)90080-0  0.539
Show low-probability matches.